Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Wealthy Get Dengue Fever, Drug Companies More Likely to Act (Asia)

This article was originally published in PharmAsia News

Executive Summary

A recent report has found that rates of dengue infection are on the rise. Singapore has reported over 5,000 infections while India has over 100,000 recorded, including over 1,000 deaths. Recorded in the journal Nature, the report notes that infection rates are becoming particularly prevalent in wealthy and middle class Asian communities. Advocates for a dengue vaccine hope this trend will encourage major pharmaceutical companies to consider developing better preventative treatments. Their involvement would be essential since developing the vaccine is likely to be a costly proposition. Experts note any vaccine would have to be capable of addressing at least four strains of the virus to prove effective. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel